Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Neural Regulation01:37

Neural Regulation

43.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.6K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
Amyloid Fibrils03:03

Amyloid Fibrils

6.8K
6.8K
Amyloid Fibrils03:03

Amyloid Fibrils

12.1K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
12.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mild cognitive impairment in Parkinson's disease: current view.

Frontiers in cognition·2026
Same author

Psychosis in Huntington disease: a short update.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

The enigma of vascular dementia: current state and emerging perspectives.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Depression and apathy in frontotemporal dementia: a short assessment of facts and outlook.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Is there a link between multiple sclerosis and Alzheimer disease? A critical note.

Journal of neural transmission (Vienna, Austria : 1996)·2025
Same author

Comorbid Pathologies and Their Impact on Dementia with Lewy Bodies-Current View.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Feb 21, 2026

Technique for Intranasal Administration of α-Synuclein Aggregates
04:49

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

1.1K

Multiple System Atrophy: An Oligodendroglioneural Synucleinopathy1.

Kurt A Jellinger1

  • 1Institute of Clinical Neurobiology, Vienna, Austria.

Journal of Alzheimer'S Disease : JAD
|October 7, 2017
PubMed
Summary

Multiple system atrophy (MSA) is a fatal neurodegenerative disease characterized by α-synuclein deposits. Current treatments are ineffective, highlighting the urgent need for research into its complex pathogenesis and potential therapeutic targets.

Keywords:
diagnostic criteriaglio-neuronal degenerationmultiple system atrophyoligodendroglial proteinopathypathogenesisprion-like seedingα-synuclein

More Related Videos

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.4K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.1K

Related Experiment Videos

Last Updated: Feb 21, 2026

Technique for Intranasal Administration of α-Synuclein Aggregates
04:49

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

1.1K
Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.4K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.1K

Area of Science:

  • Neuroscience
  • Neuropathology
  • Genetics

Background:

  • Multiple system atrophy (MSA) is a rare, fatal, adult-onset neurodegenerative disease with unknown causes.
  • It presents with parkinsonism, cerebellar, autonomic, and motor dysfunctions.
  • MSA is an α-synucleinopathy characterized by glioneuronal degeneration in specific nervous system pathways.

Purpose of the Study:

  • To review the current understanding of MSA's molecular pathogenesis.
  • To highlight the diagnostic advancements and neuropathological hallmarks.
  • To emphasize the need for novel therapeutic strategies.

Main Methods:

  • Review of existing literature on MSA pathogenesis, clinical presentation, and neuropathology.
  • Analysis of diagnostic criteria and biomarker advancements.
  • Synthesis of current knowledge on α-synucleinopathy, neuroinflammation, and cellular dysfunction in MSA.

Main Results:

  • MSA involves α-synuclein deposition in glia and neurons, leading to cytoplasmic inclusions.
  • Pathogenesis includes prion-like α-synuclein spread, oxidative stress, mitochondrial dysfunction, and neuroinflammation.
  • Despite research, no effective disease-modifying therapies currently exist for MSA.

Conclusions:

  • MSA is a complex disorder with multifactorial pathogenesis, including α-synuclein propagation and cellular dysfunction.
  • Improved diagnostic accuracy has been achieved through updated criteria and biomarkers.
  • Urgent multidisciplinary research is required to identify genetic factors, develop reliable biomarkers, and discover effective treatments for MSA.